《績後表現》禪遊(02660.HK)半年多賺近88%不派息 股價先升後跌11%
禪遊科技(02660.HK)半年多賺87.6%,高於盈喜時料增逾80%,不派中期息。該股下午再度掉頭略升破上周五盤中所創52周高位1.47元,最高見1.48元,創逾15個月高無以為繼,獲利盤湧現,最低見1.25元(剛為20天線),現造1.26元,倒跌近11%,股價失守10天線(1.31元),成交增至1,027萬股,涉資1,396萬元。
禪遊中午公布,中期純利按年升87.6%至1.32億元人民幣(下同),每股盈利13分,但不派中期息,去年同期派息5港仙。期內,營業額按年升52%至4.68億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.